Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.30 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.30 |
| ▸ | CD81 | P60033 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523130 | 0.79 | CD81 (0.35) | ALDH1A1CD81CYP2C9 | |
| SCHEMBL3868755 | 0.76 | KDM4E (0.38) | ALDH1A1CD81CYP2C9 | |
| SCHEMBL638324 | 0.76 | KDM4E (0.38) | ALDH1A1CD81CYP2C9 | |
| SCHEMBL336884 | 0.75 | — | — | |
| SCHEMBL1774515 | 0.73 | AKR1C3 (0.42) | CD81CYP2C9 | |
| SCHEMBL1774518 | 0.73 | AKR1C3 (0.42) | CD81CYP2C9 | |
| SCHEMBL7652645 | 0.72 | GRIK1 (0.36) | — | |
| SCHEMBL7652641 | 0.72 | GRIK1 (0.36) | — | |
| SCHEMBL5090509 | 0.71 | NFKB1 (0.32) | NFKB1CD81CYP2C9 | |
| SCHEMBL3331069 | 0.71 | NFKB1 (0.32) | NFKB1CD81CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070113353-A1 | Polymeric Surface Treatment Compositions | THE CLOROX COMPANY | 2007-05-24 | — | — | US | claimed |
| US-8821841-B2 | Copolymers for cosmetic applications | BASF SE (DE) | 2014-09-02 | — | — | US | disclosed |
| US-20100160487-A1 | Polymeric Surface Treatment Compositions | THE CLOROX COMPANY (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100135918-A1 | COPOLYMERS FOR COSMETIC APPLICATIONS | BASF SE (DE) | 2010-06-03 | — | — | US | disclosed |
| US-7699941-B2 | Polymeric surface treatment compositions | THE CLOROX COMPANY (US) | 2010-04-20 | — | — | US | disclosed |
| US-20080199416-A1 | Free radically polymerized, crosslinked copolymer of vinylpyrrolidone-methacrylic acid-vinylimidazole-C16-C18-polyethylene glycol methacrylate- ethylene glycol dimethacrylate; quaternized with methyl chloride or methyl sulfate; neutralized with triethanolamine; hair spray, shampoo, cosmetics | BASF AKTIENGESELLSCHAFT (DE) | 2008-08-21 | — | — | US | disclosed |
| US-20070113353-A1 | Polymeric Surface Treatment Compositions | THE CLOROX COMPANY | 2007-05-24 | — | — | US | disclosed |
| US-6579517-B1 | Crosslinked, water soluble polyurethane; hair setting | BASF AKTIENGESELLSCHAFT (DE) | 2003-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080199416-A1 | Free radically polymerized, crosslinked copolymer of vinylpyrrolidone-methacrylic acid-vinylimidazole-C16-C18-polyethylene glycol methacrylate- ethylene glycol dimethacrylate; quaternized with methyl chloride or methyl sulfate; neutralized with triethanolamine; hair spray, shampoo, cosmetics | PCNA, PHOSPHO1, SGMS2 | NFKB1 3745/4885ALDH1A1 2217/4885GAA 4717/4885 |
| US-20100135918-A1 | COPOLYMERS FOR COSMETIC APPLICATIONS | CUTA, ACMSD, FFAR3 | NFKB1 4333/4885ALDH1A1 309/4885GAA 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.